DDR biomarker: An algorithm system for DNA Damage Response agents to identify responders to WEE1 inhibition

Debiopharm logo, AI DDR Biomarker for WEE1 Inhibitor Response

Debiopharm, a leading developer of therapeutics targeting DNA Damage Response (DDR), is collaborating with Genialis to develop a model aimed at optimizing patient stratification for their WEE1 tyrosine kinase inhibitor. Historically, the complexity of DDR biology has limited the efficacy and durability of monotherapies, necessitating patient selection and rational combinations, both requiring accurate and information-rich biomarkers.

Translating DDR biology into an AI predictor

  • Pinpoint Pathways
    We dissected DDR’s complexities to identify critical biological processes and interactions influencing therapy response and resistance

  • Rapidly Configure the Algorithm
    We configured a biomarker algorithm comprising numerous biological modules representing various biologies contributing to DDR therapeutic vulnerability

  • Refine and Validate on In-vivo Data
    Developing a Debiopharm proprietary model using existing translational and clinical data to enhance the biomarker’s predictive power for patient response

  • Explore Clinical Deployment
    Genialis continues to collaborate with Debiopharm to refine the biomarker and explore its potential integration into clinical trials

Advancing clinical development of a WEE1 targeted therapy

In early 2025, Genialis announced an extension of its collaboration with Debiopharm to develop a predictive biomarker for WEE1-targeted therapy. Debiopharm’s WEE1 asset is currently in Phase 1 clinical research and is being studied as monotherapy and in multiple combinations in collaboration with international partners.

AACR 2025: WEE1 Response Predictor

At the AACR in April 2025,  we presented a first-generation digital biomarker built with the Genialis™ Supermodel. It was capable of predicting responders from non-responders to the Debio 0123 WEE1 inhibitor.

ESMO AI 2025: WEE1 Combination Predictor

A new predictor was showcased at the ESMO AI conference in November 2025. It was able to stratify patients receiving Wee1 inhibitor and carboplatin combination therapy.